YUNNAN BAIYAO(SZ:000538)2024-06-04 10:28Group 1: Sales Performance - In 2023, Yunnan Baiyao toothpaste held a domestic market share of 24.60%, maintaining the top position in the market [2] - During the "Double 11" shopping festival, Yunnan Baiyao's flagship store on Tmall achieved over 100 million in sales for the first time, becoming the first flagship store to reach this milestone with a single toothpaste product [2] - Other traditional Chinese medicine products, such as Pudilan Anti-inflammatory Tablets and Huoxiang Zhengqi Water, achieved sales revenues exceeding 100 million, with year-on-year growth of approximately 16% and 124%, respectively [4] Group 2: Marketing Strategies - The company employs a dual approach of online and offline marketing to enhance brand exposure and expand market share [2] - Online strategies include collaborations with major e-commerce platforms and creative live streaming on platforms like Douyin [2] - Offline promotions included over 14,700 events across 1,465 cities, enhancing brand visibility through various campaigns [3] Group 3: Future Outlook - The company aims to position itself as a comprehensive health solution provider, focusing on the pharmaceutical industry and strengthening its core competencies [5] - Future strategies will emphasize the core position of traditional Chinese medicine, enhancing the competitive capacity of the entire industry chain [5] - The company plans to develop a strategic investment capability and risk management system to support healthy and efficient growth of core and innovative businesses [6] Group 4: R&D Progress - Yunnan Baiyao's subsidiary received approval for clinical trials of Fluorobufen Gel Patch, which is intended for pain relief and anti-inflammatory treatment [6]